Cellectis and Weill Cornell Collaborate to Develop New Leukaemia Immunotherapies

Cellectis, a French biopharmaceutical firm, has entered into a translational research collaboration with Weill Cornell Medical College situated in the US. The alliance will aim to fast-track development of a targeted immunotherapy for patients with acute myelogenous leukaemia (AML). The partnership will be combining Cellectis’ work in the development and manufacture of gene edited CAR

Continue Reading

J&J and GlaxoSmithKline’s Sirukumab Phase III Trials Begin

GlaxoSmithKline and Johnson & Johnson (J&J) announced yesterday that they have started Phase III clinical trials of their investigational rheumatoid arthritis (RA) treatment, sirukumab. Johnson & Johnson’s Janssen Biologics unit in Ireland and GlaxoSmithKline have begun a Phase III development programme for sirukumab (otherwise known as CNTO 136), a human anti-interleukin (IL)-6 monoclonal antibody.  The

Continue Reading

Parexel Partners in Early-Phase Research with UH Bristol

Parexel yesterday announced that they have extended their alliance network for early-phase research by partnering with University Hospitals Bristol National Health Service Foundation Trust (UH Bristol), which is one of the UK’s biggest specialist training and research hospital trusts. With this arrangement Parexel continues to increase their network, which complements the US-based biopharmaceutical services company’s

Continue Reading